Activist 3i, LP Continues Selling Valion Bio Shares While Converting Preferred Stock
VBIO sits 27% above its 52-week low of $0.112 on elevated volume (13× avg).
Summary
Activist investor 3i, LP sold 443,361 shares of Valion Bio common stock between August 20-24, 2026, while converting 2.02 million preferred shares, maintaining a 9.9% ownership stake.
Key Events · Ownership and Investor Activity · VBIO
-
3i, LP Sells 443,361 Shares
Activist investor 3i, LP sold 403,324 shares on Aug 20 at $0.1221, 18,486 shares on Aug 21 at $0.1143, and 21,551 shares on Aug 24 at $0.1763, totaling 443,361 shares sold.
-
Converts 2.02M Preferred Shares
3i, LP converted 2,020,404 shares of Series C Preferred Stock at $0.39 per share on August 20, 2026, adding to its common stock position.
-
Maintains 9.9% Ownership
Despite the sales, 3i, LP retains beneficial ownership of 2,102,780 shares (9.9% of 20,913,373 outstanding), including 135,482 shares issuable upon warrant exercise and note conversion.
-
Activist Campaign Continues
This filing follows 3i's successful push to replace the CEO and secure $3 million in funding, with the activist now monetizing part of its position while retaining control through preferred stock and warrants.
Analysis · VBIO · Life Sciences
Activist investor 3i, LP sold an additional 443,361 shares of Valion Bio common stock between August 20 and August 24, 2026, at prices ranging from $0.1143 to $0.1763, while simultaneously converting 2,020,404 shares of Series C Preferred Stock at $0.39 per share. The sales represent a continued reduction of 3i's position even as it maintains a 9.9% beneficial ownership stake through conversions and warrants. This activity follows 3i's successful campaign to replace the CEO and secure board control, suggesting the activist is monetizing part of its investment while retaining influence through preferred stock and warrants.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 29.4% of the 2796 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $0.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $0.11 to $3.32. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.